Destanni Henderson Parents, Articles B

Investors. Employees must meet all eligibility requirements in order to qualify. Note to new hires: Access to enrollment site will begin 3-5 days after your hire date. #BMSCareers. The stock's 50-day moving average price is $64.07 and its 200-day moving average price is $62.55. In November, the company announced that the Phase 3 CheckMate -816 trial met the co-primary endpoint of improved event-free survival (EFS) in patients with resectable Stage IB to IIIA non-small cell lung cancer. A replay of the conference call will be available beginning at 11:30 a.m. We believe people learn the most through on-the-job experiences. Apr 27, 2021 (The Expresswire) -- Covid -19 Impact to global Stroke Treatment Drugs Market for 2015-2025. The tender offer described in this communication has not yet commenced. The companys lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Learn more about the cookies we use on our General Privacy Notice page. The 2022 Country 2 Country 4 Cancer ride organised by Bristol Myers Squibb will feature more than 90 of the company's employees cycling in seven European countries from 2-19th September in support of the Union for International Cancer Control (UICC) and selected members to raise funds with the aim of accelerating the fight against cancer and 0000005253 00000 n Up to 100% of qualifying tuition costs may be covered, based upon manager discretion and budget. NEW YORK-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE:BMY) today reports results for the fourth quarter and full year of 2021, which reflect strong sales driven by robust commercial execution and significant advancement of the company's pipeline that further progressed the company's portfolio renewal. ET on February 4 through 11:30 a.m. Bristol-Myers June 17 (Reuters) - Bristol-Myers Squibb Co BMY.N and Eisai Co said on Thursday they had entered into an A Reminder to Patients Applying to the Bristol Myers Squibb Patient Assistance Foundation (BMSPAF) If you are applying to BMSPAF for the first time or for continued assistance, your application may be processed more quickly if you include proof of your household income from a Federal Tax Return or other sources of income documentation including: [Updated: 3/26/2021] BMY Stock Looks Undervalued At $63. Elizabeth Mily joined Bristol Myers Squibb Co. as executive vice president of strategy and business development in March 2020 after 27 years in investment banking. Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) plus Yervoy (ipilimumab) for Treatment of Mismatch Repair Deficient or Microsatellite InstabilityHigh Metastatic Colorectal Cancer After Prior Chemotherapy. Mily spoke to S&P Global Market Intelligence ahead of the 2021 J.P. Morgan Healthcare Conference beginning Jan. 11 about the company's plans for future M&A and partnerships. schedule conferences . ***Included as part of the key loss of exclusivity (LOE) brands, *In excess of +100%. 0000042788 00000 n Certain other significant tax items are also excluded such as the impact resulting from internal transfers due to streamlining our legal entity structure subsequent to the Celgene acquisition and the global intangible low taxed income tax change upon finalization of the Otezla* divestiture in 2020. Tuesday, November 16, 2021. Bristol-Myers Squibb's revenue was $11,406 million in Q4 2022, showing mixed results compared to previous quarters, and there are many explanations for this, which will be discussed in the article . bristol myers squibb holiday calendar 2021. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today's research reports here >>>Bristol-Myers Squibb's shares . The 2022 non-GAAP EPS guidance is further explained under Use of Non-GAAP Financial Information. The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this press release. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures for a particular quarterly period are available on the companys website at www.bms.com., Risk Evaluation and Mitigation Strategies (REMS), Pre-Approval Access to Investigational Medicines, Areas of Interest & Competitive Research Grants, The Thomas O. Daniel Research Incubator and Collaboration Center, Acquisition FAQs for Celgene Shareholders, Acquisition-related information for Celgene shareholders, Unsubscribe to News Email Alerts - Bristol Myers Squibb, Subscribe to New Email Alerts - Bristol Myers Squibb, BMS at June 2022 oncology and hematology congresses, Committed to creating a better future for cancer patients, People & Business Resource Groups leadership team, Our Commitment to Equal Employment Opportunity, Access to Medicines in the Developing World, UK-CA Slavery and Human Trafficking Statement (PDF), Our Commitment to Global Inclusion & Diversity>. Bristol-Myers Squibb's report follows an earnings beat by J&J on January 26, who reported EPS of $1.86 on revenue of $22.48B, compared TipRanks Team May 19, 2021. Bristol-Myers Squibb 2021: Mark Your Calendar. (Reuters) - A judge in Hawaii on Monday ordered Bristol-Myers Squibb (NYSE: BMY) Co and Sanofi (NASDAQ: SNY) SA Following the sale, the senior vice president now directly owns 16,243 shares in the company, valued at $1,042,963.03. The transaction was unanimously approved by both the Bristol Myers Squibb and Turning Point Therapeutics Boards of Directors and is anticipated to close during the third quarter of 2022. You may read any reports, statements or other information filed by the company or Turning Point Therapeutics with the SEC at no charge on the SECs website at www.sec.gov. Repotrectinib has been granted three Breakthrough Therapy Designations from the U.S. Food and Drug Administration. Learn more! Listen to Webcast. When adjusted for foreign exchange impact, international revenues increased 7%. Moving to the bottom line, Bristol Myers Squibb grew its non-GAAP EPS by 22.7% YOY to $2.00 in the third quarter. Learn about joining our global team! %PDF-1.5 % Connect with a more experienced colleague to be your sounding board and to help guide you forward. Toggle Dropdown. The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. Cautionary Statement Regarding Forward-Looking Statements. 867 0 obj Income tax benefit was approximately $510 million despite pre-tax earnings of $1.9 billion in the quarter primarily due to the impact of internal transfers of certain intangible assets of $1.0 billion. 0000007256 00000 n Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of investigational medicines designed to target the most common mutations associated with oncogenesis. The extension will allow sufficient time to review information pertaining to updates of the proposed Risk Evaluation Mitigation Strategy (REMS). Leixlip, Kildare. Copyright 20082023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Former Sales Training Manager in nullnull, Current Maintenance Engineer in Manati, PR, Puerto Rico, Current Senior Manufacturing Engineer in New Brunswick, NJ, New Jersey, Former Senior Financial Analyst in Princeton, NJ, New Jersey. General Manager Development: We partner with the premier CEDEP organization to build our future General Manager talent through this internationally recognized program. 0000002778 00000 n Upcoming events. A reconciliation of the forward-looking non-GAAP measures presented in this communication is not provided due to the inherent difficulty in forecasting and quantifying items that are necessary for such reconciliation. As a result, the reconciliation of these non-GAAP measures to the most directly comparable GAAP measures is not available without unreasonable effort. Materials related to the call will be available at the same website prior to the conference call. Such risks, uncertainties and other matters include, but are not limited to: increasing pricing pressures from market access, pharmaceutical pricing controls and discounting; changes to tax and importation laws and other restrictions in the United States, the European Union and other regions around the world that result in lower prices, lower reimbursement rates and smaller populations for whom payers will reimburse; changes under the 340B Drug Pricing Program; challenges inherent in new product development, including obtaining and maintaining regulatory approval; the companys ability to obtain and protect market exclusivity rights and enforce patents and other intellectual property rights; the possibility of difficulties and delays in product introduction and commercialization; the risk of certain novel approaches to disease treatment (such as CAR T therapy); industry competition from other manufacturers; potential difficulties, delays and disruptions in manufacturing, distribution or sale of products, including without limitation, interruptions caused by damage to the companys and the companys suppliers manufacturing sites; the impact of integrating the companys and Celgenes business and operations, including with respect to human capital management, portfolio rationalization, finance and accounting systems, sales operations and product distribution, pricing systems and methodologies, data security systems, compliance programs and internal controls processes; the risk of an adverse patent litigation decision or settlement and exposure to other litigation and/or regulatory actions; the impact of any healthcare reform and legislation or regulatory action in the United States and international markets; increasing market penetration of lower-priced generic products; the failure of the companys suppliers, vendors, outsourcing partners, alliance partners and other third parties to meet their contractual, regulatory and other obligations; regulatory decisions impacting labeling, manufacturing processes and/or other matters; the impact on the companys competitive position from counterfeit or unregistered versions of its products or stolen products; the adverse impact of cyber-attacks on the companys information systems or products, including unauthorized disclosure of trade secrets or other confidential data stored in the companys information systems and networks; the companys ability to execute its financial, strategic and operational plans; the companys ability to identify potential strategic acquisitions, licensing opportunities or other beneficial transactions; the companys dependency on several key products; any decline in the companys future royalty streams; the companys ability to effectively manage acquisitions, divestitures, alliances and other portfolio actions and to successfully realize the expected benefits of such actions; the companys ability to attract and retain key personnel; the impact of the companys significant additional indebtedness that it incurred in connection with the Celgene acquisition and the MyoKardia acquisition; political and financial instability of international economies and sovereign risk; interest rate and currency exchange rate fluctuations, credit and foreign exchange risk management; the impact of adverse outcomes in lawsuits, claims, proceedings and government investigations; the impact of our exclusive forum provision in our by-laws for certain lawsuits on our stockholders ability to obtain a judicial forum that it finds favorable for such lawsuits; issuance of new or revised accounting standards; and risks relating to public health outbreaks, epidemics and pandemics, including the impact of the COVID-19 pandemic on the companys operations. And while our work transforms the lives of patients, it also transforms the lives and careers of those who do it. Cautionary Statement Regarding Forward-Looking Statements. 07/29/21 : Interim 2021 Earnings Release (Projected) 10/28/21 : Q3 2021 Earnings Release (Projected) 01/27/22 : FY 2021 Earnings Release (Projected) 04/28/22 Bristol-Myers would pay $650 million, including for research and development expenses to Eisai, which will also be eligible for up to $2.45 billion in milestone payments, the companies said. The accounting treatment as a business combination or asset acquisition will be determined upon the expected close of the transaction in the third quarter of 2022. Learn about our safety approach to COVID-19 > At Bristol Myers Squibb, the work you do-often in support of emerging therapeutic areas that require new methods of thinking and working-will help people prevail over serious diseases. Ensure day-day logistics operations are meet. hA 04Fq\GczC. I n the latest trading session, Bristol Myers Squibb (BMY) closed at $67.34, marking a -0.07% move from the previous day. Yield Attractiveness B 3.27% forward dividend yield. Kitchenettes with vending machines, free coffee and tea. The basis for our security efforts is to protect our employees, operations and intellectual property. . In addition, non-GAAP gross margin, which is gross profit excluding certain specified items as a percentage of revenues, non-GAAP operating margin, which is operating income excluding certain specified items as a percentage of revenues; non-GAAP free cash flow, which is non-GAAP net earnings plus adjustments related to cash generated from operating activities and cash paid for capital expenditures; non-GAAP marketing, selling and administrative expenses, which is marketing, selling and administrative expense excluding certain specified items, and non-GAAP research and development expenses, which is research and development expenses excluding certain specified items, are relevant and useful for investors because they allow investors to view performance in a manner similar to the method used by our management and make it easier for investors, analysts and peers to compare our operating performance to other companies in our industry and to compare our year-over-year results. We foster an energizing work experience, that through your choices, education and access, sustains our environment of well-being, individual accountability, productivity and safety. Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in a fireside chat at the 2021 Bank of America Securities Virtual Health Care Conference, which will be webcast on Tuesday, May 11, 2021. Month List Download. Case Timeline November 12, 2021 PRESS RELEASE: FTC Approves Modifications to Bristol Meyers Squibb Divestiture Agreement January 13, 2020 File Complaint (112.81 KB) File Usually give off For the year end holidays too! FOURTH QUARTER PRODUCT REVENUE HIGHLIGHTS, *In excess of +100%. paid time off and holidays- employees are expected to work holidays at times. though we are required to work bank holidays, Paid holidays for employees are always offered, they add weeks off at times. 0000005488 00000 n ET. The transaction is expected to be up to $0.08 per share dilutive to non-GAAP EPS in 2022 prior to any impact from an acquired in-process research and development charge based on final accounting treatment. This was driven by its aforementioned revenue growth, a 330-basis-point. If you have $1,000 at the ready, pharmaceutical stock Bristol Myers Squibb *Stock Advisor returns as of June 7, 2021. Neither the company nor Turning Point Therapeutics undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. A copy of the tender offer statement and the solicitation/recommendation statement will be made available to all stockholders of Turning Point Therapeutics free of charge at tptherapeutics.com. 0000011978 00000 n The company has a current ratio of 1.67, a quick ratio of 1.58 and a debt-to-equity ratio of 0.82. Use of Non-GAAP Financial Information and Financial Guidance, In discussing financial guidance, Bristol Myers Squibb refers to financial measures that are not in accordance with U.S. Generally Accepted Accounting Principles (GAAP). **Included as part of the new product portfolio Here we feature several BMS colleagues sharing their views on the subject from their perspectives, based on their own experiences. For your convenience, specialized Bristol Myers Squibb representatives are available by phone or email to help you with your medical, technical, or general inquiries. Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. Key 2022 GAAP and non-GAAP line-item guidance assumptions are: The 2022 financial guidance excludes the impact of any potential future strategic acquisitions and divestitures, and any specified items that have not yet been identified and quantified. Bristol Myers Squibb will not tolerate practices that violate the intent of our Mission and Commitment. Operating expenses, consisting of marketing, selling and administrative expenses and research and development expenses, are expected to decrease by approximately 10% for GAAP and be in-line with 2021 levels for non-GAAP. In addition to day to day coaching and mentoring, members of Rosh Chodesh. Source: Bristol-Myers Squibb The transaction is the biggest acquisition ever announced so early in a calendar year, according to data compiled by Bloomberg going back to 1990. We calculate foreign exchange impacts by converting our current-period local currency financial results using the prior period average currency rates and comparing these adjusted amounts to our current-period results. Forward-looking statements contained on this website should be evaluated together with the many uncertainties that affect Bristol Myers Squibb's business, particularly those identified in the cautionary factors discussion in the companys most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. Bristol Myers Squibb Company BMY announced that the Committee for Medicinal Products Holiday Calendar; Repligens earnings estimates for 2021 Bristol Myers Squibbs 1Q Results Miss Estimates; Street Says Buy. Forward-looking statements contained on this website should be evaluated together with the many uncertainties that affect Bristol Myers Squibb's business, particularly those identified in the cautionary factors discussion in the companys most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. Bristol-Myers Squibb BMY | stock $69.02 0.09% $147 B 3.31% $2.28 - Ratings - BMY Dividend Safety A+ 16 years of consecutive dividend increase. 0000015083 00000 n hb```b``{Ab,GU\r``8e/Gu sMJM ;xxDFD>]/=nxoEA2nlt2Tr2\+lcGC=!Rq(t=-SPMHj>Ytv@! We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure. 0000115702 00000 n Non-GAAP EPS . Every year, key managers and executives are required to certify that they have read, understand, are in compliance with, and will continue to comply with our Standards of Business Conduct and Ethics. . Shareholders who. endstream We are committed to following all laws regarding child labor, forced labor and freedom of association. Currency in USD Follow 2W 10W 9M 70.18 -1.22 (-1.71%) At close: 04:00PM EST 70.40 +0.22 (+0.31%) After hours: 07:43PM EST Time. "Bristol Myers Squibb is well positioned to build on our success in 2021 and continue to grow our company through the end of the decade." Giovanni Caforio Posted: October 12, 2021 Full-Time At Bristol Myers Squibb, we are inspired by a single vision - transforming patients' lives through science. The news made me sad as I found her career path quite inspiring Bristol-Myers Squibb reported sales of $10.13 billion during the same quarter last year, which would suggest a positive year-over-year growth rate of 11.8%. I'm ready to enroll! 3 floating holidays. 33 days holiday (inc. bank holidays) - prorated - with the option to buy/sell 5 additional days ; ET on April 29, 2021 Bristol-Myers Squibb (NYSE:BMY) SVP Adam Dubow sold 3,119 shares of the business's stock in a transaction dated Wednesday, May 5th. Jun 11, 2021 5:45PM EDT. Learn about Bristol Myers Squibb Paid Holidays, including a description from the employer, and comments and ratings provided anonymously by current and former Bristol Myers Squibb employees. 0000007493 00000 n Bristol Myers Squibb Vacation & Paid Time Off 344 employees reported this benefit 4.4 54 Ratings Available to US-based employees Change location Employer Verified Mar 7, 2022 Employee Comments Showing 1-10 of 54 Jan 28, 2023 4.0 Current Direcror in nullnull Comparable to big Pharma company Helpful Report Dec 22, 2022 4.0 Bristol Myers Squibb (NYSE: BMY) looks very attractive at current levels of $63, as The Max Foundation and Bristol-Myers Squibb are teamed up to help even more people around the globe face cancer with dignity and hope. Whether it's bringing key medicines to market, or expanding patient access to medicines, our commitment to patients drives innovation in our pipeline and guides our action as a responsible corporate citizen. Recently declared a week off fro everybody between xmas and new years. , M@C(c{H?X8 G ,Lv9 A00Lbd`d: p` Bristol-Myers Squibb Co (BMY) Stock Price & News - Google Finance Home BMY NYSE Bristol-Myers Squibb Co Follow Share $69.30 After Hours: $69.30 (0.00%) 0.00 Closed: Mar 3, 4:02:47 PM GMT-5. Glassdoor is your resource for information about the Paid Holidays benefits at Bristol Myers Squibb. xref Gordon Dyal & Co., LLC is serving as the exclusive financial advisor to Bristol Myers Squibb, and Kirkland & Ellis LLP is serving as legal counsel. Sales from key loss of exclusivity (LOE) brands, which represent. Add to Google Calendar. This led to the automatic termination of the CVR agreement Jan. 1,2021 rendering the CVRs as ineligible for payment under the agreement. (PDF), UK-CA Slavery and Human Trafficking Statement (PDF), Our Commitment to Global Inclusion & Diversity>. ***Included as part of the key loss of exclusivity (LOE) brands, FOURTH QUARTER PRODUCT AND PIPELINE UPDATE, In December, the company issued its 2021 Global Access Report that detailed Bristol Myers Squibbs efforts and progress towards advancing access to healthcare and health equity globally through its own efforts and in partnership with other stakeholders. Analysts estimate that Bristol-Myers Squibb will report an earnings per share (EPS) of $1.72. Is Bristol Myers Squibb (BMY) Stock Outpacing Its Medical Peers This Year? There are no upcoming events. Shareholders. The Bristol-Myers Squibb Benefits Program gives you the flexibility and opportunity to choose from a variety of options. The Office of Corporate Conduct is a resource for any employee to confidentially and anonymously report their concerns or raise questions. The companys performance in the first quarter of 2021 Furthermore, one of the three required milestones for payment of the Bristol Myers Squibb Contingent Value Right (CVR) remained unaccomplished due to the pending FDA approval as of Dec. 31, 2020. Youll find valuable developmental opportunities to help connect you to your passion and drive your career forward. Normal for industry. We are proud of our companys global commitment to Inclusion & Diversity and the meaningful steps we are taking to drive equitable advancement and outcomes for all. This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the acquisition of Turning Point Therapeutics by the company and the development and commercialization of certain biological compounds. If, like us, you believe in the power of science to address some of the most challenging diseases of our time, then youll fit right in as we search for the next breakthroughs in biopharma. 0000013014 00000 n 0000006923 00000 n Mirati Therapeutics MRTX reported a loss of $3.51 per share for fourth-quarter 2022, narrower than the Zacks . Mar 02, 2023 (Prime PR Wire via Comtex) -- This "Organ Transplant Rejection Medication Market" study analyses the market and offers thorough insights to help. Bristol-Myers Squibb is a multinational pharmaceutical company headquartered in New York City. FDA MedWatch at 1-800-FDA-1088, and Celgene Corporation, a Bristol-Myers Squibb Company, at 1-888-423-5436. Holiday Calendar; Earnings Calendar; A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. Required to work every rotating weekends, some holidays, and during adverse weather conditions in support of . For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram. Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. With repotrectinib, we have the opportunity to change the standard of care and address a significant unmet medical need for ROS1-positive non-small cell lung cancer patients., Through this transaction, we will be able to harness the full potential of our precision oncology platform to advance the standard of care for cancer patients. We incent, recognize, reward and celebrate those who consistently embody our mission and behaviors to reach above and beyond, driving our business forward. Ensured work schedule for each day was achieved and liaised with all key personnel as . 0000042754 00000 n In addition, the company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. Minor Holidays . Whether recruiting from academia or the commercial biopharma sector, Mihaela explains why a move to BMS is a great career move. No additional data or studies have been requested. We believe that success of our science is measured by the lives we touch. Bristol-Myers is Eisai Co., Ltd. and Bristol-Myers Squibb Company (NYSE: 21-04897. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. 0000003347 00000 n ,,M|L7^`kBQv# |88960\epmPZyC?r= ,L*P}``rN Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire Turning Point Therapeutics for $76.00 per share. 3 floating holidays. bristol myers squibb holiday schedule 2021. par | Juin 16, 2022 | park hyung sik and park seo joon are brothers | hamiltonian path greedy algorithm | Juin 16, 2022 | park hyung sik and park seo joon are brothers | hamiltonian path greedy algorithm Play. Shareholder proposals relating to our 2021 Annual Meeting of Shareholders must be received by us at our principal executive offices, Bristol-Myers Squibb Company, 430 East 29th Street14th Floor, New York, New York 10016, Attention: Corporate Secretary, no later than November 25, 2020. Bristol Myers Squibb (BMY) posted disappointing results in the first quarter as the pharmaceutical companys revenues rose 3% Shrilekha Pethe Apr 30, 2021. 0000012578 00000 n I am confident in our ability to execute against key milestones in 2022, including three planned first-in-class launches with the fixed dose combination of relatlimab plus nivolumab, mavacamten and deucravacitinib. We routinely post important information for investors on our website, BMS.com, in the Investors section. 0000003993 00000 n (. INVESTORS AND TURNING POINT THERAPEUTICS STOCKHOLDERS ARE STRONGLY ADVISED TO READ THE TENDER OFFER STATEMENT (INCLUDING AN OFFER TO PURCHASE, LETTER OF TRANSMITTAL AND RELATED TENDER OFFER DOCUMENTS) AND THE RELATED SOLICITATION/ RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 THAT WILL BE FILED BY TURNING POINT THERAPEUTICS WITH THE SEC, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT SHOULD BE CONSIDERED BY TURNING POINT THERAPEUTICSS INVESTORS BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. In 2021, their top products included Revlimid and Opdivo, drugs used in the treatment of certain. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item. Join scientists like Aparna's team, who have helped Bristol Myers Squibb establish a leadership position within hematology oncology therapies, doing interesting and meaningful work while transforming patients lives daily. A cash dividend payment of $0.49 per share is scheduled to be paid on November 01, 2021. Job security always hanging over your head. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell securities, nor is it a substitute for the tender offer materials that Bristol Myers Squibb and Rhumba Merger Sub Inc. (Merger Sub) will file with the U.S. Securities and Exchange Commission (SEC).